319 related articles for article (PubMed ID: 30721572)
1. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
Khoo J; Hsiang JC; Taneja R; Koo SH; Soon GH; Kam CJ; Law NM; Ang TL
Liver Int; 2019 May; 39(5):941-949. PubMed ID: 30721572
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL
J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
[TBL] [Abstract][Full Text] [Related]
4. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
[TBL] [Abstract][Full Text] [Related]
5. Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model.
Fang T; Huang S; Chen Y; Chen Z; Chen J; Hu W
Exp Clin Endocrinol Diabetes; 2021 Sep; 129(9):625-633. PubMed ID: 32961563
[TBL] [Abstract][Full Text] [Related]
6. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
7. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.
Jensen SBK; Sørensen V; Sandsdal RM; Lehmann EW; Lundgren JR; Juhl CR; Janus C; Ternhamar T; Stallknecht BM; Holst JJ; Jørgensen NR; Jensen JB; Madsbad S; Torekov SS
JAMA Netw Open; 2024 Jun; 7(6):e2416775. PubMed ID: 38916894
[TBL] [Abstract][Full Text] [Related]
8. Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial.
Lim SL; Johal J; Ong KW; Han CY; Chan YH; Lee YM; Loo WM
JMIR Mhealth Uhealth; 2020 Apr; 8(4):e14802. PubMed ID: 32281943
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive lifestyle intervention
Deibert P; Lazaro A; Schaffner D; Berg A; Koenig D; Kreisel W; Baumstark MW; Steinmann D; Buechert M; Lange T
World J Gastroenterol; 2019 Mar; 25(9):1116-1131. PubMed ID: 30862999
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Armstrong MJ; Hull D; Guo K; Barton D; Hazlehurst JM; Gathercole LL; Nasiri M; Yu J; Gough SC; Newsome PN; Tomlinson JW
J Hepatol; 2016 Feb; 64(2):399-408. PubMed ID: 26394161
[TBL] [Abstract][Full Text] [Related]
12. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers.
Mazzotti A; Caletti MT; Brodosi L; Di Domizio S; Forchielli ML; Petta S; Bugianesi E; Bianchi G; Marchesini G
J Hepatol; 2018 Nov; 69(5):1155-1163. PubMed ID: 30290973
[TBL] [Abstract][Full Text] [Related]
13. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.
Zhu W; Feng PP; He K; Li SW; Gong JP
Biochem Biophys Res Commun; 2018 Oct; 505(2):523-529. PubMed ID: 30269815
[TBL] [Abstract][Full Text] [Related]
15. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
Petit JM; Cercueil JP; Loffroy R; Denimal D; Bouillet B; Fourmont C; Chevallier O; Duvillard L; Vergès B
J Clin Endocrinol Metab; 2017 Feb; 102(2):407-415. PubMed ID: 27732328
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
18. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial.
Wong VW; Chan RS; Wong GL; Cheung BH; Chu WC; Yeung DK; Chim AM; Lai JW; Li LS; Sea MM; Chan FK; Sung JJ; Woo J; Chan HL
J Hepatol; 2013 Sep; 59(3):536-42. PubMed ID: 23623998
[TBL] [Abstract][Full Text] [Related]
19. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Zhang LY; Qu XN; Sun ZY; Zhang Y
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):674-680. PubMed ID: 32113823
[TBL] [Abstract][Full Text] [Related]
20. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]